Cargando…

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

BACKGROUND: In clinical practice, temporary interruption of rheumatoid arthritis (RA) therapy is common for various reasons including side effects, non-compliance, or necessity for surgery. To characterize temporary interruptions of baricitinib and placebo-matched tablets in phase 3 studies of patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emery, Paul, Tanaka, Yoshiya, Cardillo, Tracy, Schlichting, Douglas, Rooney, Terence, Beattie, Scott, Helt, Cameron, Smolen, Josef S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227095/ https://www.ncbi.nlm.nih.gov/pubmed/32414425 http://dx.doi.org/10.1186/s13075-020-02199-8

Ejemplares similares

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
por: Keystone, Edward C, et al.
Publicado: (2015)

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
por: Smolen, Josef S, et al.
Publicado: (2017)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
por: Emery, Paul, et al.
Publicado: (2021)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
por: Smolen, Josef S, et al.
Publicado: (2020)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
por: Schiff, Michael, et al.
Publicado: (2017)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018)

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial
por: Michaud, Kaleb, et al.
Publicado: (2019)

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
por: Dougados, Maxime, et al.
Publicado: (2017)

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
por: Zhang, Xin, et al.
Publicado: (2017)

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
por: van der Heijde, Desirée, et al.
Publicado: (2019)

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
por: Taylor, Peter C., et al.
Publicado: (2019)

The sonographic identification of cortical bone interruptions in rheumatoid arthritis: a morphological approach
por: Cipolletta, Edoardo, et al.
Publicado: (2021)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022)

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
por: Keystone, Edward C, et al.
Publicado: (2017)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?
por: Zahir Hussain, Wajith Hussain, et al.
Publicado: (2021)

Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
por: Pope, Janet E., et al.
Publicado: (2021)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Interrupts-List
por: Cherix, E
Publicado: (1990)

Trends of adverse events and mortality after DMARDs in patients with rheumatoid arthritis: Interrupted time‐series analysis
por: Fang, Yao‐Fan, et al.
Publicado: (2022)

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
por: Taylor, Peter C., et al.
Publicado: (2023)

The science of rheumatoid arthritis: a prelude
por: Smolen, Josef S
Publicado: (2005)

Rheumatoid arthritis
por: Tanaka, Yoshiya
Publicado: (2020)

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis
por: Koumaki, Dimitra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_luem5b9nf8k656tqvamq422u87